SCHEDULE: Tang Capital Reduces Stake in Bolt Biotherapeutics

Tang Capital Management and affiliated entities have reduced their beneficial ownership in Bolt Biotherapeutics, Inc. to 3.5% of outstanding common stock.

Summary

• Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP, and Tang Capital Partners International, LP collectively beneficially own 66,879 shares of Bolt Biotherapeutics, Inc. common stock.
• This represents 3.5% of the company's outstanding common stock.
• The ownership percentage is based on 1,919,441 shares outstanding as of August 7, 2025, as reported in the Issuer's Form 10-Q filed on August 14, 2025.
• The reporting persons share both voting and dispositive power over these shares.
• This filing is Amendment No. 4 to a Schedule 13G, indicating a change in their previously reported ownership, which implies a reduction in their stake.
• The reporting persons certify that the securities were not acquired or held for the purpose of changing or influencing control of the issuer, except for activities related to nominations under Rule 14a-11.

Sentiment

Score: 3

Explanation: The reduction in beneficial ownership by a significant institutional investor, as indicated by the amendment to a Schedule 13G and the current stake falling below 5%, generally signals a negative sentiment or reduced conviction in the company's future prospects from that investor's perspective.

Positives

• NA

Negatives

• The reduction in beneficial ownership by Tang Capital Management and its affiliates to 3.5% suggests a potential decrease in conviction or a strategic divestment by a significant institutional investor.
• This divestment could be interpreted negatively by the market, potentially signaling a less favorable outlook on Bolt Biotherapeutics' future prospects.

Risks

• Reduced institutional investor confidence: The decrease in ownership by Tang Capital Management and its affiliates could signal a diminished outlook on Bolt Biotherapeutics' future prospects or performance.
• Potential for further divestment: A reduction in stake might precede further sales, potentially putting downward pressure on the stock price.

Future Outlook

NA

Industry Context

This filing indicates a change in a significant institutional investor's position in Bolt Biotherapeutics, a company operating in the biotechnology sector. While the filing itself doesn't provide industry-specific details, a reduction in stake by a prominent capital management firm could be interpreted by the market as a signal regarding the firm's view on the company's prospects within the competitive biotech landscape.

Comparison to Industry Standards

• NA

Stakeholder Impact

• Shareholders: May react negatively to the news of a significant institutional investor reducing its stake, potentially leading to downward pressure on the stock price.
• Company Management: Might need to address investor concerns or provide clarity on the company's strategy and performance to reassure the market.

Next Steps

• NA

Key Dates

Recommendation

The reduction in beneficial ownership by Tang Capital Management and its affiliates to 3.5% from a previously higher, undisclosed stake (implied by the Amendment No. 4 filing) suggests a loss of conviction from a sophisticated institutional investor. While the filing itself doesn't provide reasons, such a divestment by a notable fund often signals potential concerns about the company's future performance or valuation. This could lead to negative market sentiment and potential downward pressure on the stock, warranting a 'sell' recommendation for investors seeking to mitigate risk or reallocate capital.

Keywords

Bolt Biotherapeutics, Tang Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Shareholding, SEC Filing, Biotechnology